Investigators reported practice patterns and clinical outcomes of second-line therapies in patients with primary refractory metastatic renal cell carcinoma (RCC).

Clinicians and their patients with chronic kidney disease (CKD) need to be aware of zinc intake and anemia status.

This is the first-in-human phase 1/2a trial of Treg and bone marrow transplantation in HLA-mismatched living donor kidney transplant recipients.